Background-We previously demonstrated that conditional overexpression of neuronal nitric oxide synthase (nNOS) inhibited L-type Ca 2ϩ channels and decreased myocardial contractility. However, nNOS has multiple targets within the cardiac myocyte. We now hypothesize that nNOS overexpression is cardioprotective after ischemia/reperfusion because of inhibition of mitochondrial function and a reduction in reactive oxygen species generation. Methods and Results-Ischemia/reperfusion injury in wild-type mice resulted in nNOS accumulation in the mitochondria.
S everal studies in recent years have investigated the effects of neuronal nitric oxide synthase (nNOS) exerted on cardiomyocytes, with special emphasis on the intracellular localization of nNOS. However, results from pharmacological inhibition and genetic deletion or from conditional overexpression of nNOS brought divergent results. Interestingly, despite the fact that current studies demonstrated discrepant findings in terms of myocardial contractility and Ca 2ϩ homeostasis, it seems consistent that nNOS is upregulated and is cardioprotective in different models of heart disease. [1] [2] [3] In this context, different targets of nNOS relevant in Ca 2ϩ cycling, eg, RyR2, 4 L-type Ca 2ϩ channel, 5 SERCA2a, 6 and PLN, 7 were identified in the past. Additionally, cardioprotective effects have also been ascribed to exert on the cardiac xanthine oxidoreductase (XOR). nNOS suppresses the activity of the cardiac XOR, which is one of the major sources of O 2 Ϫ production in the heart. It has been shown that this targeted inhibition maintains the balance between the production of reactive nitrogen species and reactive oxygen species (ROS) 3, 8, 9 in cardiac tissues. nNOS, also found in mitochondria, 10, 11 inhibits the mitochondrial respiratory chain, resulting in inhibition of ATP production. NO reversibly binds to the oxygen binding site of cytochrome c oxidase, reacting either with the oxidized copper to give inhibitory nitrite or with the reduced heme, resulting in reversible inhibition in competition with oxygen. 12 However, it has also been suggested that NO derived from nNOS does not directly contribute to the inhibition of mitochondrial respiration but rather represents an antioxidant system by inhibiting XOR activity. 8
Clinical Perspective on p 1603
To elucidate the impact of abundant nNOS on cardiomyocyte function, we assessed the direct and subcellular effects of conditional overexpression of nNOS after ischemia/reperfu-sion injury. We hypothesized that nNOS acts cardioprotective via a decrease in superoxide formation and differential effects on mitochondrial respiration.
Methods

Animal Model
In brief, the induction of nNOS overexpression by removal of doxycycline was started a minimum of 10 days before any experiment. Animals of both genders were used. The mice used for experiments were Ͻ3 months of age. Myocardial nNOS protein expression was increased Ͼ6-fold in the overexpressing animals (627Ϯ13% versus 100Ϯ7%; nϭ19; PϽ0.01) as reported earlier. 5 For more details, see the online-only Data Supplement.
Infarct Size Measurement After Ischemia/Reperfusion
Infarct size measurements and ischemia/reperfusion experiments were performed as recently described. 13 After triphenyl tetrazolium chloride staining, viable myocardium stains red and the infarcted areas appear pale. For more details, see the online-only Data Supplement.
In Vitro Ischemia/Reperfusion Experiments With Isolated Hearts
Mice were anesthetized by injection of pentobarbital intraperitoneally. Retrograde perfusion of the heart was started in the Langendorff mode at 37°C at a constant coronary perfusion pressure of 100 mm Hg. Oxygenated Krebs-Henseleit buffer was used for perfusion. A water-filled balloon was inserted into the left ventricle and fixed by a ligature. The balloon was connected to a Statham P23Db pressure transducer (Gould Statham Instruments) for continuous measurement of left ventricular pressure. Hearts were subjected to 20 minutes of ischemia followed by reperfusion. The specific nNOS inhibitor S-methyl-L-thiocitrulline acetate salt (SMTC) was administered at a final concentration of 0.125 mg/kg.
Electron Microscopy With Immunogold Labeling
In brief, for electron microscopy, the excised hearts were fixed in 4% paraformaldehyde and embedded in LR White (Sigma, Munich, Germany). For detection of the transgene nNOS, a polyclonal anti-6xHN antibody 1:50 (BD Biosciences, San Jose, Calif) was used, followed by a secondary antibody coupled to 12-nm gold particles. For detection of all nNOS in electron microscopy, a polyclonal anti-nNOS antibody 1:50 (Zymed) was used, followed by a second antibody that was coupled to 6-nm gold particles; simultaneously, a monoclonal anti-cytochrome c oxidase antibody 1:200 (MitoSciences) was used, followed by a second antibody that was coupled to 12-nm gold particles. For more details, see the onlineonly Data Supplement.
Immunofluorescence Staining of Isolated Adult Cardiac Myocytes
The isolated adult cardiac myocytes were plated on laminin-coated slides. After fixation, cells were incubated in 2% avidin and 2% biotin. The polyclonal anti-nNOS antibody 1:50 (Zymed) was used overnight. The next day, cells were probed with biotinylated antirabbit IgG 1:300 followed by avidin D fluorescence antibody 1:300. The monoclonal anti-cytochrome c 1:100 antibody also was used (MitoSciences).
Protein Expression in Isolated Mitochondria (nNOS, L-type Ca 2؉ Channel, SERCA2a)
Enriched mitochondrial fraction from mouse heart was prepared according to a modified protocol developed by R&D Systems (Minneapolis, Minn). Mitochondria were further enriched on a gradient of Percoll (See the online-only Data Supplement for more details). For Western blot analysis, mitochondria samples were probed with purified mouse monoclonal anti-nNOS antibody 1:200 (BD Transduction Laboratories), polyclonal anti-L-type Ca 2ϩ channel antibody 1:500 (Alomone Laboratories), or polyclonal anti-SERCA2a antibody 1:5000 (Badrilla). As a loading control, antiprohibitin antibody 1:200 (abcam) was used.
Coimmunoprecipitation Experiments
Frozen hearts were homogenized in radioimmunoprecipitation assay buffer. The coimmunoprecipitation experiments were done with the Immunoprecipitation Starter Pack (GE Healthcare). Protein 300 to 600 g was used. Antigens were coupled to 2.5 g purified antibody (anti-nNOS, anti-inducible NOS [iNOS], or anti-endothelial NOS [eNOS]; all Transduction Laboratories). Western blot analysis was performed with monoclonal anti-heat shock protein 90 (HSP90) antibody 1:5.000 (abcam).
Transfection of Neonatal Rat Cardiomyocytes and Treatment With Geldanamycin
Isolated neonatal cardiomyocytes were plated in MEM/5 on 6-well plates at a density of 1 million cells per well. Forty-eight hours after preparation, cells were transfected with lipofectamine (Invitrogen, Carlsbad, Calif). The transfection was performed with the nNOS plasmid described earlier. 5 Cells were treated with 2 mol/L geldanamycin (a specific inhibitor of HSP90 activity). After 24 hours, mitochondria were isolated and Western blot analysis was performed. Mitochondria samples were probed with purified mouse monoclonal anti-nNOS antibody 1:200 (BD Transduction Laboratories). Anti-cytochrome c antibody was used as a loading control.
Nitrite Level in Isolated Mitochondria
This measurement was performed with a modified version of the Nitric Oxide Colorimetic Assay Kit from Biomol. See the onlineonly Data Supplement for more details.
Cytochrome c Oxidase Activity
Cytochrome c oxidase activity was measured with a modified version of the Cytochrome C Oxidase Assay Kit from Sigma. Instead of DTT, 10 mmol/L ascorbate was used to reduce cytochrome c, followed by removal of the reductant by passage through a Sephadex G-25 column. The colorimetric assay in this kit is based on the observation of a decrease in absorbance at 550 nm ferrocytochrome c caused by its oxidation to ferricytochrome c by cytochrome c oxidase. Whole mouse hearts were homogenized in radioimmunoprecipitation assay buffer, and mitochondria were isolated as described above. Protein concentration was measured, and a final concentration of 0.4 g/L was used for the assay. Activity was measured with a kinetic program: 5-second delay, 10-second interval, 6 readings, and room temperature. To investigate whether cytochrome c oxidase activity was inhibited by NO binding to cysteine or to the heme, we added either DTT or hemoglobin. DTT (50 mol/L) or hemoglobin (4 mol/L) was added, and measurement of cytochrome c oxidase activity was started immediately.
Myocardial O 2 ؊ Consumption
O 2 Ϫ consumption measurements were performed as described previously. 14 
O 2 ؊ Production in Isolated Mitochondria
O 2 Ϫ production was determined by the oxidation of mitohydroethidine (Mito-HE/MitoSOX Red; Invitrogen) to 2-hydroxymito-ethidium with high-performance liquid chromatography-electrochemical analysis as described previously with some modifications. 15 Mitochondria were isolated from the left ventricle with the Qproteome Mitochondria Isolation Kit (QIAGEN). Isolated mitochondria were incubated with Mito-HE (10 mol/L), and the conversion to 2-hydroxy-mito-ethidium was monitored by highperformance liquid chromatography-electrochemical analysis.
ROS Concentration
To measure the concentration of ROS in homogenized hearts, the TAC-Peroxyl assay kit (Applied Bioanalytical Labs) was used. To determine whether the ROS are produced by the NADPH oxidase or XOR, heart samples were incubated with different inhibitors: apocynin (300 mol/L for 30 minutes at 37°C) as an inhibitor for NADPH oxidase and allopurinol (0.1 mmol/L for 1 minute at room temperature) for XOR (see the online-only Data Supplement).
NADPH Oxidase Activity and Protein Expression of NADPH Oxidase Subunits
NADPH oxidase activity was measured in homogenized hearts (radioimmunoprecipitation assay buffer) by lucigenin-enhanced chemiluminescence. Then, 100 g protein lysate was incubated with 1 mmol/L lucigenin and 300 mol/L NADPH, and luminescence was recorded for 20 minutes in 30-second intervals.
Western blot analysis was performed for different subunits of the NADPH oxidase (p47 PHOX , p67 PHOX , and rac 1). Protein samples were probed with purified mouse monoclonal anti-rac 1 antibody 1:500, purified mouse monoclonal anti-p47 PHOX antibody 1:500, or purified mouse monoclonal anti-p67 PHOX antibody (all BD Transduction Laboratories). As a loading control, anti-GAPDH antibody 1:8000 (chemicon) was used.
XOR Activity and Protein Expression
The measurement of XOR activity was carried out with the Amplex Red Xanthine Oxidase Assay Kit (Molecular Probes, Carlsbad, Calif; see the online-only Data Supplement). For Western blot analysis of XOR protein expression, samples were probed with purified rabbit polyclonal anti-XOR antibody 1:1000 (abcam). As a loading control, anti-GAPDH antibody 1:8000 (chemicon) was used. 
Statistical Analysis
Results nNOS Reduced Infarct Size In Vivo After Ischemia/Reperfusion Injury
The infarct size within the area at risk was significantly decreased in nNOS-overexpressing nNOS ϩ /␣MHC-tTA ϩ mice compared with noninduced nNOS ϩ /␣MHC-tTA ϩ animals (median, 37.5%, Q . 25 Figure 1A and 1B and Figure II in the online-only Data Supplement).
Recovery of Left Ventricular Developed Pressure After Ischemia/Reperfusion Injury in Isolated Hearts
To assess functional recovery after in vitro ischemia/reperfusion experiments, isolated hearts of nNOS-overexpressing (nϭ12) and noninduced nNOS ϩ /␣MHC-tTA ϩ animals (nϭ12) were investigated. Left ventricular developed pressure (LVDP) increased at a higher rate in hearts of nNOSoverexpressing nNOS ϩ /␣MHC-tTA ϩ mice than in hearts of the noninduced mice (average LVDP increase 30 minutes after ischemia, 0.603 mm Hg/min in noninduced animals versus 1.598 mm Hg/min in nNOS-overexpressing nNOS ϩ / ␣MHC-tTA ϩ mice; nϭ12; Figure 1C and Table I in the online-only Data Supplement), even though LVDP was significantly higher before ischemia in noninduced nNOS ϩ / ␣MHC-tTA ϩ mice (median, 88.95 mm Hg in hearts of noninduced animals versus 72.0 mm Hg in hearts of nNOSoverexpressing animals; Pϭ0.0001). Application of SMTC again weakens the positive effects of the transgene nNOS overexpression (estimated average LVDP increase, 0.832 mm Hg/min; nϭ12). Recovery of ventricular function was improved over the whole reperfusion period in nNOSoverexpressing animals. Heart rate did not differ significantly between groups (noninduced, 558Ϯ33 bpm; nNOS overexpressing, 581Ϯ27 bpm; nNOS overexpressing plus SMTC, 567Ϯ21 bpm; nϭ12; PϭNS). Rate-pressure product was changed in parallel to LVDP ( Figure I in the online-only Data Supplement). Both in vivo and in vitro ischemia/reperfusion experiments showed a cardioprotective effect of conditional myocardial nNOS overexpression.
nNOS Protein Expression in the Mitochondria
To investigate the subcellular distribution of nNOS, we performed immunogold labeling, immunofluorescence staining, and Western blot analysis. Electron microscopy of mouse myocardium from noninduced and nNOS-overexpressing nNOS ϩ /␣MHC-tTA ϩ animals showed that nNOS is additionally localized in mitochondria after the induction of nNOS expression ( Figure 2A ). Immunogold labeling was positive for the 6xHN tag that indicated conditional nNOS overexpression. Immunogold labeling also showed a close proximity of nNOS and cytochrome c oxidase in the mitochondria ( Figure 2B and 2C). We also performed immunofluorescence staining of isolated adult cardiac myocytes ( Figure III in the online-only Data Supplement). These images indicated a colocalization of nNOS and cytochrome c oxidase (as mitochondrial marker) in nNOS-overexpressing nNOS ϩ /␣MHC-tTA ϩ mice.
To confirm these results, we isolated mitochondria from hearts of noninduced and nNOS-overexpressing nNOS ϩ / ␣MHC-tTA ϩ mice. Western blot analysis showed a significantly increased nNOS protein expression in isolated mitochondria of nNOS-overexpressing nNOS ϩ /␣MHC-tTA ϩ mice (median, 219.70 relative percent, Q . 25 Figure 2D ). To test for contamination of the isolated mitochondria, we performed different Western blot analyses of isolated mitochondria. Figure 2E shows no detectable protein expression of L-type Ca 2ϩ channel and SERCA2a in either noninduced nNOS ϩ /␣MHC-tTA ϩ animals or nNOS-overexpressing nNOS ϩ /␣MHC-tTA ϩ mice. For control experiments on contamination, see also Figure IV in the online-only Data Supplement.
Of note, endogenous nNOS is also located at the mitochondria in noninduced nNOS ϩ /␣MHC-tTA ϩ animals, but endogenous nNOS was increased in isolated mitochondria of wild-type mouse hearts after ischemia/reperfusion (median, 306.70 relative percent, Q . 25 Figure 2F ).
Translocation of nNOS to Mitochondria
To analyze the transport mechanism of nNOS into mitochondria, we performed coimmunoprecipitation experiments. Coimmunoprecipitation analysis showed an interaction between nNOS and HSP90 in both noninduced and nNOSoverexpressing nNOS ϩ /␣MHC-tTA ϩ mice. Notably, immunoreactivity in the nNOS-overexpressing mice was stronger than in the noninduced animals. There was no interaction between iNOS and HSP90, whereas the interaction between eNOS and HSP90 again was detectable in both nNOSoverexpressing nNOS ϩ /␣MHC-tTA ϩ and noninduced nNOS ϩ /␣MHC-tTA ϩ mice ( Figure 3A ). To further assess the mechanism of nNOS translocation, neonatal rat cardiomyocytes were transfected with nNOS and treated with geldanamycin (a specific inhibitor of HSP90 activity). Western blot analyses of isolated mitochondria showed a significant suppression of nNOS protein expression in geldanamycin-treated cardiomyocytes (median, 17.19 relative percent, Q .25 /Q .75 , 6.25/31.25 relative percent versus median, 100.00 relative percent, Q .25 /Q .75 , 90.63/109.38 relative percent; nϭ11; PϽ0.0001; Figure 3B ). Obviously, nNOS is shuttled into the Figure 1 . A, Infarct size within the area at risk was significantly reduced in nNOS-overexpressing nNOS ϩ /␣MHC-tTA ϩ mice. Application of the specific nNOS inhibitor SMTC (0.125 mg/kg) inhibited the nNOS effects. B, The area at risk was not significantly changed in the 3 different groups of animals (nNOS-overexpressing, noninduced, and nNOS-overexpressing nNOS ϩ /␣MHC-tTA ϩ mice treated with SMTC). C, LVDP was significantly increased in isolated hearts of nNOS-overexpressing nNOS ϩ /␣MHC-tTA ϩ mice compared with noninduced nNOS ϩ /␣MHC-tTA ϩ animals in vitro even though LVDP was significantly higher before ischemia in noninduced animals. Application of the specific nNOS inhibitor SMTC to nNOS-overexpressing animals inhibited LVDP recovery. Functional recovery was significantly improved during reperfusion in nNOS ϩ /␣MHC-tTA ϩ animals. mitochondria via interaction with HSP90, which was sufficiently inhibited by geldanamycin.
Nitrite Level of Isolated Mitochondria and Impairment of Cytochrome c Oxidase Activity
It was previously shown that endogenous NO reversibly inhibits oxygen consumption and ATP synthesis by compet-itive inhibition of cytochrome c oxidase. Here, we demonstrated that nitrite levels were significantly increased in isolated mitochondria of nNOS-overexpressing nNOS ϩ / ␣MHC-tTA ϩ mice compared with noninduced littermates (median, 18.65 mol/L, Q .25 /Q .75 , 14.78/19.72 mol/L versus median, 11.15 mol/L, Q .25 /Q .75 , 10.25/12.10 mol/L; nϭ10; PϽ0.0001; Figure 4A ). Simultaneously, nNOS overexpression significantly suppressed cytochrome c oxidase activity (median, 71.50 U/mL, Q .25 /Q .75 , 63.93/81.23 U/mL versus median, 111.75 U/mL, Q .25 /Q .75 , 108.83/115.48 U/mL; nϭ12; PϽ0.0001; Figure  4B ) and first-order rate constant (Ϫ0.0089 first-order rate constant of nNOS-overexpressing mice versus Ϫ0.01779 first-order rate constant of noninduced animals; nϭ7; PϽ2 eϪ16 ; Figure 4C and Table II in the online-only Data Supplement). To investigate whether cytochrome c oxidase activity was inhibited by NO binding to cysteine or to the heme, we added either DTT (which destroyed S-nitrosothiols) or hemoglobin (which scavenged NO of the heme in cytochrome c oxidase).
Application of DTT completely reversed the inhibiting effect of nNOS overexpression (Ϫ0.0089 first-order rate constant of nNOS-overexpressing mice versus Ϫ0.0178 firstorder rate constant of nNOS-overexpressing animals plus DTT; nϭ7; PϽ2 eϪ16 ). In contrast, application of hemoglobin further suppressed cytochrome c oxidase activity significantly (Ϫ0.00321 versus Ϫ0.0089 first-order rate constant; nϭ7; PϽ2 eϪ16 ; Figure 4D and Table III in the online-only Data Supplement). Application of DTT had no significant Figure 2 (Continued) . C, Immunogold labeling of mouse myocardium from noninduced nNOS ϩ /␣MHC-tTA ϩ and nNOS-overexpressing nNOS ϩ /␣MHC-tTA ϩ animals. The polyclonal anti-nNOS antibody was used, followed by a second antibody that was coupled to 6-nm gold particles; simultaneously, the monoclonal anti-cytochrome c oxidase antibody was used, followed by a second antibody that was coupled to 12-nm gold particles. The anti-nNOS antibody used in this experiment was reactive for both endogenous and overexpressed nNOS. In nNOS-overexpressing nNOS ϩ / ␣MHC-tTA ϩ mice, there was a close proximity between cytochrome c oxidase and nNOS. Black circles indicate cytochrome c oxidase; red circles, nNOS. D, Western blot analysis of isolated mitochondria showed a significantly increased total nNOS protein expression of nNOS-overexpressing nNOS ϩ /␣MHC-tTA ϩ mice compared with noninduced nNOS ϩ /␣MHC-tTA ϩ animals. The antibody for nNOS was reactive for both endogenous and overexpressed nNOS. Prohibitin (a mitochondrial marker) was used as a loading control. effect on cytochrome c oxidase activity in noninduced nNOS ϩ /␣MHC-tTA ϩ mice (Ϫ0.01779 first-order rate constant of noninduced mice versus Ϫ0.0155 first-order rate constant of noninduced animals plus DTT; nϭ7; Pϭ0.21). Again, application of hemoglobin suppressed cytochrome c oxidase activity significantly (Ϫ0.0057 versus Ϫ0.01767 first-order rate constant; nϭ7; PϽ2 eϪ16 ; Figure 4E and Table  IV in the online-only Data Supplement). From these experiments, we concluded that inhibition of cytochrome c oxidase activity is inhibited by NO binding to a cysteine thiol of cytochrome c oxidase (rather than binding to the heme).
Myocardial Oxygen Consumption
To investigate whether NO derived from nNOS directly affects myocardial oxygen consumption (MV O 2 ), we examined the effects of conditional nNOS overexpression on MV O 2 in isolated muscle strips. Already under resting conditions, we observed a significant inhibition of MV O 2 in isolated muscle strips from Figure 2 (Continued) . E, Western blot analysis of 40 g isolated mitochondria showed that there is no detectable protein expression of L-type Ca 2ϩ channel or SERCA2a in either mitochondrial preparations of noninduced nNOS ϩ / ␣MHC-tTA ϩ animals or nNOSoverexpressing nNOS ϩ /␣MHC-tTA ϩ mice. As a positive control, 10 g of rat heart membranes was used for L-type Ca 2ϩ channel Western blot, and 10 g cardiac sarcoplasmic reticulum vesicles were used for SERCA2a Western blot. Prohibitin was used as a loading control. F, Western blot analysis of isolated mitochondria of mouse wild-type hearts showed an increased nNOS protein expression after ischemia/reperfusion (WT IR). Figure 5A ). This effect was sustained during work (stimulation at 5 Hz for 30 minutes). O 2 consumption was given as ratio of MVO 2 to force-time integral (median, 69.00 relative percent, Q .25 /Q .75 , 65.50/74.00 relative percent versus median, 100.00 relative percent, Q .25 /Q .75 , 95.75/105.25 relative percent; nϭ14; PϽ0.0001; Figure 5B Figure 6A ). ROS have been implicated in cardiac dysfunction. XOR and NADPH oxidase are known to be the major enzymes generating ROS in cardiac myocytes. In this study, we investigated ROS generation during nNOS overexpression and in noninduced nNOS ϩ /␣MHC-tTA ϩ mice.
nNOS-overexpressing nNOS
The ROS concentration was significantly decreased in hearts of nNOS-overexpressing nNOS ϩ /␣MHC-tTA ϩ mice compared with noninduced animals (median, 6.08 mol/L, Q .25 /Q .75 , 5.83/6.75 mol/L versus median, 14.54 mol/L, Q .25 /Q .75 , 13.91/14.72 mol/L; nϭ8; Pϭ0.001; Figure 6B ). O 2
Ϫ is produced via several mechanisms, including XOR and NADPH oxidase. Thus, we investigated the effects of allopurinol, an inhibitor of XOR, and apocynin, an inhibitor of NADPH oxidase, in both nNOSoverexpressing and noninduced nNOS ϩ /␣MHC-tTA ϩ mice. Figure 3 . A, Coimmunoprecipitation experiments showed an interaction between both nNOS and eNOS with HSP90 in noninduced and nNOS-overexpressing nNOS ϩ /␣MHC-tTA ϩ mice. There was no interaction between iNOS and HSP90. B, Neonatal cardiomyocytes were transfected with nNOS and treated with geldanamycin (2 mol/L, an inhibitor of HSP90). Western blot analysis showed that mitochondrial nNOS protein content was significantly decreased in geldanamycin-treated cells, which indicated that mitochondrial nNOS translocation is dependent on HSP90. Cytochrome c was used as a loading control.
In noninduced nNOS ϩ /␣MHC-tTA ϩ animals, both application of apocynin (median, 14.54 mol/L, Q .25 /Q .75 , 13.91/14.72 mol/L versus median, 7.17 mol/L, Q .25 / Q .75 , 6.92/7.85 mol/L; nϭ8; PϽ0.0001) and application of allopurinol (0.1 mmol/L for 1 minute at room temperature) caused a significant decline in ROS concentration (median, 14.54 mol/L, Q .25 /Q .75 , 13.91/14.72 mol/L versus median, 2.28 mol/L, Q .25 /Q .75 , 1.95/3.07 mol/L; nϭ8; PϽ0.0001; Figure 6C ). In nNOS-overexpressing nNOS ϩ /␣MHC-tTA ϩ animals, application of apocynin also significantly inhibited ROS generation via inhibition of NADPH oxidase activity (median, 6.08 mol/L, Q .25 / Q .75 , 5.83/6.75 mol/L versus median, 3.22 mol/L, Q .25 /Q .75 , 2.97/3.43 mol/L; nϭ8; PϽ0.0001). However, in contrast to the noninduced animals, application of allopurinol had no significant inhibitory effect on ROS generation (median, 6.08 mol/L, Q .25 /Q .75 , 5.83/ 6.75 mol/L versus median, 5.36 mol/L, Q .25 /Q .75 , 4.99/ 5.69 mol/L; nϭ8; PϽ0.0001) in nNOS-overexpressing nNOS ϩ /␣MHC-tTA ϩ animals, whereas XOR activity was already suppressed by nNOS ( Figure 6D ). These data demonstrate that conditional nNOS overexpression in car-diac myocytes decreased ROS generation selectively by inhibition of XOR but had no effect on NADPH oxidase activity.
NADPH Oxidase Activity and Protein Expression
NADPH oxidase is one major enzyme generating ROS. It catalyzes the production of superoxide from oxygen and NADPH. It is a complex enzyme consisting of 2 membranebound elements (gp91 PHOX and p22 PHOX ), 3 cytosolic components (p67 PHOX , p47 PHOX , and p40 PHOX ), and a lowmolecular-weight protein (either rac 1 or rac 2).
Measurement of NADPH oxidase activity in hearts of nNOS-overexpressing and noninduced animals showed no significant difference (median, 98.30 relative percent, Q .25 / Q .75 , 96.70/104.00 relative percent versus median, 100.00 relative percent, Q .25 /Q .75 , 98.00/103.00 relative percent; nϭ7; Pϭ0.522; Figure 7A ).
Protein expression of p47 PHOX , p67 PHOX , and rac 1 was investigated by Western blot analyses. Only protein expression of rac 1 (important for the activation of the NADPH oxidase) was significantly reduced in nNOS-overexpressing mice (median, 108.41 relative percent, Q .25 /Q .75 , 85.96/ Figure 7B ), whereas protein expression of p47 PHOX (median, 99.50 relative percent, Q . 25 relative percent, Q .25 /Q .75 , 124.96/142.43 relative percent; nϭ10; Pϭ0.06) was not significantly changed ( Figure 7C ).
XOR Activity and Protein Expression
XOR activity was significantly decreased in nNOSoverexpressing mice (median, 0.091 nU/mL, Q .25 /Q .75 , 0.084/ 0.095 nU/mL versus median, 0.397 nU/mL, Q .25 /Q .75 , 0.381/ 0.418 nU/mL; nϭ8; Pϭ0.001; Figure 8A ).
Protein expression of XOR was investigated by Western blot analysis. XOR protein expression of nNOSoverexpressing mice showed no significant difference compared with noninduced animals (median, 94.44 relative percent, Q .25 /Q .75 , 87.04/111.11 relative percent versus median, 120.37 relative percent, Q .25 /Q .75 , 103.70/124.07 relative percent; nϭ7; Pϭ0.073; Figure 8B ). These results were consistent with the results of ROS generation.
Discussion
Recent studies have consistently demonstrated that nNOS is cardioprotective in different disease states. Specifically, nNOS has been shown to delay the transition to heart failure in response to pressure overload, 2 to protect the myocardium from functional deterioration after myocardial infarction, 1 and to decrease mortality after myocardial infarction. 3 In contrast, the precise molecular mechanisms of nNOS action in the myocardium during rest and after myocardial damage are still being debated.
In a model with nNOS overexpression restricted to cardiac myocytes, we recently demonstrated that nNOS decreased myocardial contractility via inhibition of the [I Ca(L) ] amplitude and [Ca 2ϩ ] i transients. 5 We now additionally identified mitochondria and XOR as further targets for nNOS in this model. Because suppression of XOR activity by nNOS has been linked to improved outcome after myocardial infarction, we now hypothesized that nNOS also is cardioprotective after ischemia/reperfusion injury. Indeed, we found preserved LVDP and a significant decrease in infarct size after ischemia/reperfusion injury in nNOS-overexpressing animals.
In further studies on subcellular localization of nNOS, we found a strong enrichment of overexpressed nNOS and low levels of endogenous nNOS in mitochondria. After ischemia/ reperfusion injury, endogenous nNOS was also clearly accumulated in the mitochondria. This was interesting in the context that mitochondria play an important role in cell death and cardioprotection. It has been demonstrated that endogenous NO interacts with mitochondrial respiration at several steps of the electron transfer, 12 although some groups doubt the existence of nNOS and the production of significant NO levels via NOS in mitochondria. 16, 17 Recent findings support the notion that the PDZ-binding domain of the nNOS isoforms that are expressed in striated muscle (nNOS␣ and Ϫ production was measured in isolated mitochondria of nNOS-overexpressing nNOS ϩ /␣MHC-tTA ϩ and noninduced nNOS ϩ /␣MHC-tTA ϩ mice. O 2
Ϫ production was significantly reduced in nNOS-overexpressing nNOS ϩ /␣MHC-tTA ϩ mice. B, The ROS concentration was significantly decreased in hearts of nNOS-overexpressing mice. C and D, ROS production is caused by XOR. In noninduced nNOS ϩ /␣MHC-tTA ϩ animals, application of apocynin (NADPH oxidase inhibitor) and allopurinol (XOR inhibitor) caused a significant decline in ROS concentration. In nNOS-overexpressing nNOS ϩ /␣MHC-tTA ϩ animals, application of apocynin also inhibited ROS generation significantly. However, in contrast to the noninduced animals, application of allopurinol had no significant inhibitory effect on ROS generation in nNOS-overexpressing nNOS ϩ /␣MHC-tTA ϩ animals. nNOS) is responsible for interaction with specific binding partners and for targeted subcellular localization. The nNOS adaptor protein CAPON (also known as NOS1AP) was demonstrated to be important for routing nNOS from the sarcoplasmic reticulum to the plasma membrane after myocardial infarction. nNOS-CAPON complexes were also found within mitochondria. 18 Here, we demonstrated that nNOS overexpression potently inhibited myocardial oxygen consumption mainly as a result of inhibition of cytochrome c oxidase. This is in line with earlier findings 12, 19 but raises 2 questions: How is nNOS translocated into the mitochondria, and how can nNOS produce NO in mitochondria where it is in competition for O 2 with other enzymes of the respiratory chain?
We now identified HSP90 as a carrier protein to translocate nNOS across the outer mitochondrial membrane to cytochrome c oxidase via the TOM complex. This could be specifically inhibited by the HSP90 inhibitor geldanamycin. Similarly, a recent study described HSP90 as the carrier responsible for translocation of connexin 43 into the mito- Figure 7 . A, There was no significant difference between noninduced and nNOS-overexpressing animals in terms of NADPH oxidase activity. B, Western blot analysis of rac 1 (a low-molecular-weight G protein important for the activation of NADPH oxidase) protein expression showed a significant decrease in hearts of nNOS-overexpressing animals compared with noninduced mice. C, Western blot analysis showed no significant difference in the protein expression of the cytosolic components p47 PHOX and p67 PHOX of NADPH oxidase. GAPDH was used as a loading control.
chondria, providing protection from ischemia/reperfusion injury. 20 Damy et al 21 also reported an increased HSP90-nNOS interaction in failing human hearts.
However, the K M values for nNOS are rather high, so nNOS might be substrate limited by oxygen in an area close to the cytochrome c oxidase. However, besides NO generation via NOS enzymes, NO generation independent of the NOS enzymes was described earlier. 22 Hemoglobin and myoglobin can reduce nitrate and nitrite to NO. In our nNOS-overexpressing mouse model, the abundant nNOS generated elevated levels of NO as published earlier. 5 This NO then is likely to be oxidized to nitrite by ceruloplasmin. 23 Nitrite from this source might serve as an NO store once ischemia occurs. Accordingly, we found significantly increased nitrite levels in isolated mitochondria from nNOSoverexpressing mice.
In a scenario with low oxygen tension (like ischemia), it has been demonstrated previously that hemoglobin and myoglobin can form NO from nitrite at low oxygen apart from NOS enzymes. 22, 24 Clearly, nitrite had to be formed by abundant NO previously. NO from these nitrite sources might then inhibit cytochrome c oxidase during acute ischemia. After translocation of nNOS to the mitochondria, as occurs in ischemia/reperfusion injury and during subsequent reperfusion with gradually increasing O 2 levels, NO that is generated from nNOS at the mitochondria might then take over and continue to inhibit cytochrome c oxidase (which might be easier at this point because cytochrome c oxidase was inhibited earlier and could therefore not compete for O 2 ). Accordingly, we found increased nitrite levels in isolated mitochondria from nNOS-overexpressing mice that are in favor of this mechanism. Recent work already identified NO derived from the other NOS enzymes (eNOS, iNOS) as factors responsible for cardioprotection in ischemia and reperfusion. It was demonstrated that iNOS inhibited mitochondrial permeability transition, and the authors suggested that iNOS acts upstream of mitochondrial permeability transition. 25 In addition, in the case of eNOS overexpression, the protective effect has been consistently demonstrated by several studies. 26 -28 An explanation for this effect might come from a study in eNOSoverexpressing animals in which Massion et al showed that eNOS, targeted to caveolae in cardiomyocytes, attenuated the effect of high concentrations of catecholamines. 29 Therefore, all 3 NOS isoforms as a net effect decreased ischemic damage. However, it appears that the molecular and subcellular processes behind this uniform protection are different for each case.
From further experiments with isolated muscle strips, we found that increased nNOS expression decreased myocardial contractility and simultaneously decreased myocardial oxygen consumption both at work and at rest. Especially from the decrease in MVO 2 at rest, we concluded that an increase in nNOS expression might act as preconditioning measure before ischemia/reperfusion.
During ischemia, ATP depletion leads to a rise in Ca 2ϩ , which further accelerates ATP depletion. The rise in Ca 2ϩ during ischemia and reperfusion leads to mitochondrial Ca 2ϩ accumulation, particularly during reperfusion when oxygen is reintroduced. This can result in opening of the mitochondrial permeability transition pore, which further compromises cellular energetics. If downregulation of mitochondrial function occurs before ischemia, this may downregulate cellular energetics and prevent cell death.
To this end, however, it is not fully clear whether this direct effect of nNOS on mitochondrial function is cardioprotective or detrimental because one would expect that inhibition of mitochondrial function cuts off energy supply. In contrast and of particular interest, it was observed that S-nitrosoglutathione treatment resulted in increased S-nitrosylation of the mitochondrial F1-ATPase, which resulted in decreased activity. It has been reported that approximately half of the ATP generated during ischemia by glycolysis is consumed by the reverse mode of the mitochondrial F1-ATPase. Therefore, inhibition of the F1-ATPase during ischemia would conserve ATP. Inhibition of the F1-ATPase could thus be beneficial by conserving cytosolic ATP and by reducing Ca 2ϩ uptake into the mitochondria. 30 Additional effectors of ischemia/reperfusion injury in cardiomyocytes are ROS. Reducing ROS has already been reported to reduce ischemic injury. 31 In this study, we have shown that the overexpression of nNOS in cardiac tissue balances the production between the production of ROS and NO. Notably, in a similar study, XOR activity was elevated at baseline in NOS1 Ϫ/Ϫ relative to wild-type mice and remained persistently elevated, whereas wild-type mice exhibited a transient elevation that was restored to normal by 4 weeks after myocardial infarction. 3 This phenomenon is in accordance with our findings demonstrating decreased XOR activity in nNOS-overexpressing mice, resulting in lower ROS levels. NADPH oxidase activity was not altered by nNOS overexpression. Mitochondrial ROS generation was also decreased in our nNOS-overexpressing animals. It has been shown that S-nitrosylation of the complex I of the electron transport chain inhibited the activity of this complex and decreased mitochondria-derived ROS formation. 32 The mechanisms underlying nNOS-and eNOS-mediated cardiac protection after myocardial infarction include the maintenance of an equilibrium between ROS and reactive nitrogen species in different cellular compartments. In infarcted nNOS Ϫ/Ϫ mice, there is a clear mismatch between the increase in ROS, especially in that resulting from XOR activity and NO production. XOR activity is persistently upregulated after myocardial infarction in nNOS Ϫ/Ϫ mice, whereas it increases transiently in control mice after myocardial infarction. The increased XOR activity was attributed to diminished XOR inhibition in the absence of nNOS-derived NO. Therefore, the absence of nNOS within the myocardium creates a nitroso-redox imbalance that was shown to be sustained in both acute and chronic myocardial infarction. 3, 31 We can now demonstrate that reducing ROS, possibly by overexpression of nNOS, reduced ischemic injury.
Recently, an additional mechanism for the protective effects of nNOS translocation has been suggested in a study by Sun and colleagues, 33 who examined male and female mice after ischemia/reperfusion. A major membrane target for nNOS after translocation appeared to be the L-type Ca 2ϩ channel. In female hearts, there was increased S-nitrosylation of the L-type Ca 2ϩ channel. Functionally, this led to decreased L-type Ca 2ϩ current [I Ca(L) ] with reduced Ca 2ϩ entry into the cell, which in turn protected the cell from Ca 2ϩ overload injury. 30, 33 This is in line with our previous studies 5 and that of Sears et al 6 that demonstrated inhibition of [I Ca(L) ] by nNOS. In contrast, others have observed unchanged L-type Ca 2ϩ currents 34 in nNOS Ϫ/Ϫ or an increase in L-type Ca 2ϩ current density in nNOS-overexpressing animals. 2 The latter studies, however, did not focus on ischemia/reperfusion injury.
Limitations
We used isoflurane in the ischemia/reperfusion experiments. In general, volatile anesthetics seem to be cardioprotective in ischemia and therefore may bias the observed cardioprotective effects. Nevertheless, we observed a protective effect of nNOS on top of this preexisting protection by isoflurane, which we believe is in favor for our hypothesis of cardioprotection by nNOS.
Conclusions
Conditional transgenic overexpression of nNOS localizes to the mitochondria and inhibits XOR, resulting in a decrease in ROS formation. Mitochondrial respiration is also downregulated in response to nNOS accumulation at the mitochondria. Together with nNOS-mediated inhibition of L-type Ca 2ϩ currents, these multiple actions of nNOS potently protect cardiomyocytes from ischemia/ reperfusion injury. The versatile actions of nNOS at multiple subcellular sites have been demonstrated in an array of recent studies. It appears that the different kinds of cardiac disease and the different disease states are mainly responsible for the prevailing function of nNOS, depending on the respective subcellular localization.
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